Details for New Drug Application (NDA): 217585
✉ Email this page to a colleague
NDA 217585 describes OLUMIANT, which is a drug marketed by Eli Lilly And Co and MSN and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the OLUMIANT profile page.
The generic ingredient in OLUMIANT is baricitinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
The generic ingredient in OLUMIANT is baricitinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
Summary for 217585
| Tradename: | OLUMIANT |
| Applicant: | Msn |
| Ingredient: | baricitinib |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | Aug 8, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2MG | ||||
| Approval Date: | Aug 8, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 4MG | ||||
| Approval Date: | Aug 8, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
